Astellas Seeks Court Order to Block Myrbetriq Copies

shot by IP News Shots / 6:23 pm on 25 November, 2020

Astellas Pharma Inc. has filed a complaint of potential patent infringement with the US District Court for the District of Delaware alleging infringement of its drug for an overactive bladder –Myrbetriq. The complaint names Sandoz International GmbH, Aurobindo Pharma Limited and Watson Pharma Pvt. Ltd. as the defendants. Astellas seeks to have the generic copies by the manufacturers blocked until the expiry of patent and a cash compensation if manufacturing is done before expiry.

Read More at: https://news.bloomberglaw.com/ip-law/astellas-sues-to-block-myrbetriq-copies-as-new-patent-is-issued

 

Industry: Pharmaceuticals | Type of IP: Litigations